EPISODE · May 2, 2022 · 59 MIN
Christian Angermayer | Longevity Investing
from Foresight Institute Radio
How can we better invest in Biotech?Christian is an entrepreneur and investor and the founder of Apeiron Investment Group. He is Cofounder and Chairman of the board at Rejuveron. Angermeyer believes that over the next 10-20 years longevity will be the centerpoint of health research. The longevity market is 100% of the population, and many of his rich friends would spend all of their money for extra years of quality life. Rejuveron, Angermeyer’s company, will only be one of a whole sector of companies focused on aging. Having a diverse portfolio of companies allows for cross pollination of ideas. Aging should be considered a disease. In the meantime, targeting standard diseases alongside aging is a good strategy. Having reliable biomarkers continues to be one of the top priorities in the near-term for moving aging into the clinical space. Rejuveron currently operates in clinical and preclinical areas. Translating aging research is difficult because amazing scientists are often not amazing drug development people.Angermeyer also spoke on neurotech, climate change, and cryptocurrency. Session Summary: Christian Angermayer, Rejuveron | Longevity & Deep Tech Investor Q&A - Foresight Institute The Foresight Institute is a research organization and non-profit that supports the beneficial development of high-impact technologies. Since our founding in 1987 on a vision of guiding powerful technologies, we have continued to evolve into a many-armed organization that focuses on several fields of science and technology that are too ambitious for legacy institutions to support.Allison Duettmann is the president and CEO of Foresight Institute. She directs the Intelligent Cooperation, Molecular Machines, Biotech & Health Extension, Neurotech, and Space Programs, Fellowships, Prizes, and Tech Trees, and shares this work with the public. She founded Existentialhope.com, co-edited Superintelligence: Coordination & Strategy, co-authored Gaming the Future, and co-initiated The Longevity Prize. Apply to Foresight’s virtual salons and in person workshops here!We are entirely funded by your donations. If you enjoy what we do please consider donating through our donation page.Visit our website for more content, or join us here:TwitterFacebookLinkedInEvery word ever spoken on this podcast is now AI-searchable using Fathom.fm, a search engine for podcasts. Hosted on Acast. See acast.com/privacy for more information.
What this episode covers
How can we better invest in Biotech?Christian is an entrepreneur and investor and the founder of Apeiron Investment Group. He is Cofounder and Chairman of the board at Rejuveron. Angermeyer believes that over the next 10-20 years longevity will be the centerpoint of health research. The longevity market is 100% of the population, and many of his rich friends would spend all of their money for extra years of quality life. Rejuveron, Angermeyer’s company, will only be one of a whole sector of companies focused on aging. Having a diverse portfolio of companies allows for cross pollination of ideas. Aging should be considered a disease. In the meantime, targeting standard diseases alongside aging is a good strategy. Having reliable biomarkers continues to be one of the top priorities in the near-term for moving aging into the clinical space. Rejuveron currently operates in clinical and preclinical areas. Translating aging research is difficult because amazing scientists are often not amazing drug development people.Angermeyer also spoke on neurotech, climate change, and cryptocurrency. Session Summary: Christian Angermayer, Rejuveron | Longevity & Deep Tech Investor Q&A - Foresight Institute The Foresight Institute is a research organization and non-profit that supports the beneficial development of high-impact technologies. Since our founding in 1987 on a vision of guiding powerful technologies, we have continued to evolve into a many-armed organization that focuses on several fields of science and technology that are too ambitious for legacy institutions to support.Allison Duettmann is the president and CEO of Foresight Institute. She directs the Intelligent Cooperation, Molecular Machines, Biotech & Health Extension, Neurotech, and Space Programs, Fellowships, Prizes, and Tech Trees, and shares this work with the public. She founded Existentialhope.com, co-edited Superintelligence: Coordination & Strategy, co-authored Gaming the Future, and co-initiated The Longevity Prize. Apply to Foresight’s virtual salons and in person workshops here!We are entirely funded by your donations. If you enjoy what we do please consider donating through our donation page.Visit our website for more content, or join us here:TwitterFacebookLinkedInEvery word ever spoken on this podcast is now AI-searchable using Fathom.fm, a search engine for podcasts. Hosted on Acast. See acast.com/privacy for more information.
NOW PLAYING
Christian Angermayer | Longevity Investing
No transcript for this episode yet
Similar Episodes
No similar episodes found.